MEETING REPORT
Updates from the British Association of Dermatologists 91st Annual Meeting, 5–7 July 2011, London, U.K.
P. De Mozzi,
A.B. Alexandroff,
G.A. Johnston,
P. De Mozzi
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorA.B. Alexandroff
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorG.A. Johnston
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorP. De Mozzi,
A.B. Alexandroff,
G.A. Johnston,
P. De Mozzi
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorA.B. Alexandroff
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorG.A. Johnston
Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, U.K.
Search for more papers by this authorAnton B. Alexandroff. E-mail: [email protected]
Funding sources None.
Conflicts of interest A.B.A. is the Lead of the Comprehensive Local Research Networks Dermatology Specialty Group, a member of the Biologics for Psoriasis Industry Subgroup, and the Steering Group of the U.K. Dermatology Clinical Trials Network; he has received fellowships, plus educational grants, consultancy fees, acted as an investigator or a member of advisory board or a director for Pfizer, Procter & Gamble, Merck Serono, LEO Pharma, Basilea Pharmaceutica, Apodi, Genus Pharmaceuticals, GlaxoSmithKline, Medefield, EMS Research, CSD Health Research, XBioCell, Bryter Research, Genactis, Medicus, The Research House, All Global, Keyquest, Almirall and Galderma.
Summary
This is a synopsis of the significant research and clinical papers presented at the British Association of Dermatologists (BAD) meeting held on the 5–7 July 2011 in London, U.K. The conference and satellite symposia highlighted the recent biological, epidemiological and therapeutic advances in dermatology. This report is not meant as a substitute for reading the conference proceedings and related references quoted in this article.
References
- 1 Fargnoli MC, Argenziano G, Zalaudek I et al. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006; 6: 657–70.
- 2 Udayakumar D, Mahato B, Gabree M et al. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg 2010; 29: 190–5.
- 3 Bartsch DK, Sina-Frey M, Lang S et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002; 236: 730–7.
- 4 Sturm RA, Duffy DL, Box NF et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 2003; 16: 266–72.
- 5 Lin J, Hocker TL, Singh M et al. Genetics of melanoma predisposition. Br J Dermatol 2008; 159: 286–91.
- 6 Kefford RF, Newton Bishop JA, Bergman W et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17: 3245–51.
- 7 Leachman SA, Carucci J, Kohlmann W et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61: 677–14.
- 8 Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006; 19: 1–8.
- 9 Singh M, Lin J, Hocker TL et al. Genetics of melanoma tumorigenesis. Br J Dermatol 2008; 158: 15–21.
- 10 Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg 2010; 29: 210–17.
- 11 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16.
- 12 Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364: 772–4.
- 13 Da Forno PD, Fletcher A, Pringle JH et al. Understanding spitzoid tumours: new insights from molecular pathology. Br J Dermatol 2008; 158: 4–14.
- 14
Alexandroff AB,
Da Forno PD,
Johnston GA.
Lack of significance of sentinel lymph node biopsy for the prognosis and management of the atypical Spitz tumor of uncertain biologic potential.
Expert Rev Dermatol
2009; 4: 215–17.
10.1586/edm.09.15 Google Scholar
- 15 Handfield-Jones SE, Smith NP. Malignant melanoma in childhood. Br J Dermatol 1996; 134: 607–16.
- 16 Argenziano G, Scalvenzi M, Staibano S et al. Dermatoscopic pitfalls in differentiating pigmented Spitz naevi from cutaneous melanomas. Br J Dermatol 1999; 141: 788–93.
- 17 Lyon VB. The Spitz nevus: review and update. Clin Plast Surg 2010; 37: 21–33.
- 18 Situm M, Bolanca Z, Buljan M et al. Nevus Spitz – everlasting diagnostic difficulties – the review. Coll Antropol 2008; 32 (Suppl. 2): 171–6.
- 19 Barnhill RL, Argenyi ZB, From L et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999; 30: 513–20.
- 20 Spatz A, Calonje E, Handfield-Jones S et al. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999; 135: 282–5.
- 21 Mitchell DL, Paniker L, Douki T. DNA damage, repair and photoadaptation in a Xiphophorus fish hybrid. Photochem Photobiol 2009; 85: 1384–90.
- 22 Bataille V, Bykov VJ, Sasieni P et al. Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis. Br J Dermatol 2000; 143: 477–83.
- 23 Waterston K, Naysmith L, Rees JL. Physiological variation in the erythemal response to ultraviolet radiation and photoadaptation. J Invest Dermatol 2004; 123: 958–64.
- 24 Darne S, Stewart L, Farr P, Hampton P. Investigation of cutaneous photoadaptation to narrowband ultraviolet B radiation. Br J Dermatol 2011; 165 (Suppl. 1): 5.
- 25 Hamzavi I. Photoadaptation: a path toward rational phototherapy protocols. J Invest Dermatol 2006; 126: 2156–8.
- 26 Gordon PM, Saunders PJ, Diffey BL et al. Phototesting prior to narrowband (TL-01) ultraviolet B phototherapy. Br J Dermatol 1998; 139: 811–14.
- 27 Palmer RA, Aquilina S, Milligan PJ et al. Photoadaptation during narrowband ultraviolet-B therapy is independent of skin type: a study of 352 patients. J Invest Dermatol 2006; 126: 1256–63.
- 28 Golberg O, Alexandroff AB, Burd R. Seasonal variation in 2-week wait skin cancer referrals is not mirrored by changes in incidence of skin cancer; a message for service provision. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 20.
- 29 Scofield J, Hepburn N, Scharrer K et al. The costs of diagnosing and treating skin cancer using the 2-week-wait referral process. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 22–3.
- 30 Munn S, Yau M, Moss R et al. Is teledermoscopy a safe and cost-effective model for triage of pigmented lesions and suspected melanoma in the U.K.? 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 21.
- 31 Kulakov E, Cooper A. Topical imiquimod use in treatment-resistant mycosis fungoides. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 29.
- 32 Gawkrodger DJ, McLeod CW, Dobson K. Nickel skin levels in different occupations and an estimate of the threshold for reacting to a single open application of nickel in nickel-allergic subjects. Br J Dermatol 2012; 166: 82–7.
- 33 Fischer LA, Menne T, Johansen JD. Dose per unit area – a study of elicitation of nickel allergy. Contact Dermatitis 2007; 56: 255–61.
- 34 Gawkrodger DJ, Dobson K, McLeod CW. Nickel skin levels in different occupations and the threshold for reacting to nickel as a single open application in nickels-allergic subjects. Br J Dermatol 2011; 165 (Suppl. 1): 71.
- 35 Madan V, Walker SL, Beck MH. Sodium metabisulfite allergy is common but is it relevant? Contact Dermatitis 2007; 57: 173–6.
- 36 Pink A, Bannerjee P, White IR. Contact allergy to sodium metabisulphite: a red herring? Br J Dermatol 2011; 165 (Suppl. 1): 71.
- 37 Oliphant T, Mitra A, Wilkinson M. Contact allergy to sodium sulphite and its relationship to sodium metabisulphite. Br J Dermatol 2011; 165 (Suppl. 1): 77.
- 38 Vena GA, Foti C, Angelini G. Sulfite contact allergy. Contact Dermatitis 1994; 31: 172–5.
- 39 Meredith FM, Rajpara SM, Ormerod AD. Type 1 hypersensitivity to sodium metabisulphite. Br J Dermatol 2011; 165 (Suppl. 1): 78.
- 40 Davies E, Orton D. Identifying the optimal patch test concentration for methylchloroisothiazolinone and methylisothiazolinone. Contact Dermatitis 2009; 60: 288–9.
- 41 Higgins E, Kirby B, Rogers SCF, Collins P. Methylchloroisothiazolinone and methylisothiazolinone allergic contact dermatitis and the effect of patch test concentration. Br J Dermatol 2011; 165 (Suppl. 1): 72.
- 42 Zoli V, Tosti A, Silvani S et al. Moist toilet papers as possible sensitizers: review of the literature and evaluation of commercial products in Italy. Contact Dermatitis 2006; 55: 252–4.
- 43 Darne S, Horne H. Emerging allergy to methylisothiazolinone. Br J Dermatol 2011; 165 (Suppl.1): 73.
- 44 Lundov MD, Thyssen JP, Zachariae C et al. Prevalence and cause of methylisothiazolinone contact allergy. Contact Dermatitis 2010; 63: 164–7.
- 45 Moustafa M, Holden CR, Athavale P et al. Patch testing is a useful investigation in children with eczema. Contact Dermatitis 2011; 65: 208–12.
- 46 Shah M, Lewis FM, Gawkrodger DJ. Patch testing in children and adolescents: five years’ experience and follow-up. J Am Acad Dermatol 1997; 37: 964–8.
- 47 Zug KA, McGinley-Smith D, Warshaw EM et al. Contact allergy in children referred for patch testing: North American Contact Dermatitis Group data, 2001–2004. Arch Dermatol 2008; 144: 1329–36.
- 48 Hogeling M, Pratt M. Allergic contact dermatitis in children: the Ottawa hospital patch-testing clinic experience, 1996 to 2006. Dermatitis 2008; 19: 86–9.
- 49 Seidenari S, Giusti F, Pepe P et al. Contact sensitization in 1094 children undergoing patch testing over a 7-year period. Pediatr Dermatol 2005; 22: 1–5.
- 50 Wohrl S, Hemmer W, Focke M et al. Patch testing in children, adults, and the elderly: influence of age and sex on sensitization patterns. Pediatr Dermatol 2003; 20: 119–23.
- 51 Roul S, Ducombs G, Taieb A. Usefulness of the European standard series for patch testing in children. A 3-year single-centre study of 337 patients. Contact Dermatitis 1999; 40: 232–5.
- 52 Darling MI, Horn HM, McCormack SK et al. Sole dermatitis in children: patch testing revisited. Pediatr Dermatol 2011; 29: 254–7.
- 53 Toledo F, Garcia-Bravo B, Fernandez-Redondo V et al. Patch testing in children with hand eczema. A 5-year multicentre study in Spain. Contact Dermatitis 2011; 65: 213–19.
- 54 Alexandroff AB, Armstrong DJ. Psoriasis and psoriatic arthritis: association with other inflammatory diseases and comorbidities. Adv Psor Inflamm Skin Dis 2011; 2: 77–86.
- 55 Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–7.
- 56 Seidler EM, Kimball AB. Socioeconomic disability in psoriasis. Br J Dermatol 2009; 161: 1410–12.
- 57 Alexandroff AB, Novitskaya ES, Armstrong DJ. Psoriasis as a multisystem inflammatory disease. In: Advances in Medicine and Biology ( LV Berhardt, ed.), Vol. 6. Hauppauge, NY: Nova Science Publishers, 2011; 103–25.
- 58 Pickering H. The patient’s journey: living with psoriasis – the patient’s perspective. Br J Gen Pract 2010; 60: 140.
- 59 Alexandroff AB, Johnston GA. The patient’s journey: living with psoriasis – the doctors’ perspective. Br J Gen Pract 2010; 60: 141.
- 60 De MP, Johnston GA, Alexandroff AB. Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K. Br J Dermatol 2012; 166: 252–60.
- 61 Reich K, Langley RG, Papp K et al. Efficacy and safety of briakinumab vs. methotrexate in patients with moderate to severe psoriasis. 91st Annual Meeting of BAD. Br J Dermatol 2012; 165 (Suppl. 1): 4.
- 62 Reich K, Langley RG, Lebwohl M et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862–72.
- 63 De Mozzi P, Osborne J, Burd R et al. The development of malignant melanoma and squamous cell carcinoma following anti-TNF therapy in patients with psoriasis: a report of five consecutive cases. 91st Annual Meeting of BAD. Br J Dermatol 2012; 165 (Suppl. 1): 28.
- 64 Alexandroff AB, Graham-Brown RA. Report from the 67th annual meeting of the American Academy of Dermatology. Br J Dermatol 2010; 162: 12–21.
- 65 Langley RG, Strober BE, Reich K et al. Serious infections in global clinical trials of adalimumab in moderate to severe psoriasis. 91st Annual Meeting of BAD. Br J Dermatol 2012; 165 (Suppl. 1): 37–8.
- 66 Alexandroff AB, Pauriah M, Camp RD et al. More than skin deep – atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1–7.
- 67 Alexandroff AB, Novitskaya ES, Armstrong DJ. Psoriasis as a multisystem inflammatory disease. In: Advances in Medicine and Biology. V6 (Berhardt LV, ed.) Hauppauge, NY: Nova Science, 2010; 103–25.
- 68 Kumar N, Armstrong DJ. Cardiovascular disease – the silent killer in rheumatoid arthritis. Clin Med 2008; 8: 384–7.
- 69 Raftery G, Armstrong DJ. ‘Non solum...sed etiam’: added cardiac benefits of TNF alpha blockade in rheumatoid arthritis. J R Coll Physicians Edin 2008; 38: 108–11.
- 70 Friedewald VE, Cather JC, Gelfand JM et al. AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631–43.
- 71 Alexandroff AB, Pauriah M, Lang CC et al. Atherosclerosis as a systemic feature of psoriasis. Clin Exp Dermatol 2011; 36: 451–2.
- 72 Mehta NN, Azfar RS, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000–6.
- 73 Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493–9.
- 74 Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41.
- 75 MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a report of 60 cases and review of the literature. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 33.
- 76 De Mozzi P, Crichlow S, Da Forno PD et al. A case report of lichen planopilaris in a female pattern distribution. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 89.
- 77 Audrain H, Buckley D. Diphencyprone immunotherapy for viral warts in immunosuppressed patients. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 40–1.
- 78 PATCH Trial Team. Prophylactic antibiotics for the prevention of cellulitis of the leg: results of the U.K. Dermatology Clinical Trials Network’s PATCH II trial. 91st Annual Meeting of BAD. Br J Dermatol 2011; 165 (Suppl. 1): 5.
- 79 Thomas K, Crook A, Foster K et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network’s PATCH II trial. Br J Dermatol 2012; 166: 169–78.
- 80 Alexandroff AB, Burd R. Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology. Br J Dermatol 2009; 160: 938–45.
- 81 Abstracts of the British Association of Dermatologists 91st Annual Meeting, July 5–7, 2011, London, U.K. Br J Dermatol 2011; 165 (Suppl. 1): 1–143.
- 82 Levell NJ. English melanoma by body site: keep wearing the trousers? Br J Dermatol 2011; 165: 709–10.
- 83 Polom K, Murawa D, Rho YS et al. Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. Br J Dermatol 2012; 166: 682–3.
- 84 Giles N, Pavey S, Pinder A et al. Multiple melanoma susceptibility factors function in an ultraviolet radiation response pathway in skin. Br J Dermatol 2012; 166: 362–71.
- 85 Argenziano G, Longo C, Cameron A et al. Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol 2011; 165: 1251–5.
- 86 Reich K, Burden AD, Eaton JN et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179–88.
- 87 Honigsmann H. Comparison of psoralen plus ultraviolet A therapy and biologics in moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 455–6.
- 88 Alexandroff AB. Once more unto the breach. Inaugural meeting of the British Society for Immunology Tumour Immunology Affinity Group. Cancer Immunol Immunother 1996; 43: 254–5.
- 89 Husein El-Ahmed H, Garrido-Pareja F, Ruiz-Carrascosa JC et al. Vessel resistance to blood flow in the nailfold in patients with psoriasis: a prospective case–control echo Doppler-based study. Br J Dermatol 2012; 166: 54–8.
- 90 Sureda N, Phan A, Poulalhon N et al. Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review. Br J Dermatol 2011; 165: 852–8.
- 91 Hoffmann JH, Hartmann M, Enk AH et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011; 165: 1355–8.
- 92 Nikolaou V, Kang X, Stratigos A et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011; 165: 1219–22.
- 93 Alexandroff AB, Dalgleish AG. Cancer biologists hit the road. Molecular genetics of cancer: Second Joint Conference of the American Association for Cancer Research and the European Association for Cancer Research. Oxford, UK, 9–13 September 1997. Cancer Gene Therapy Symposium. London, UK, 23–24 June 1997. Mol Med Today 1997; 3: 524–7.
- 94 Suppa M, Elliott F, Mikeljevic JS et al. The determinants of periorbital skin ageing in participants of a melanoma case–control study in the U.K. Br J Dermatol 2011; 165: 1011–21.
- 95 Miteva M, Tosti A. The follicular triad: a pathological clue to the diagnosis of early frontal fibrosing alopecia. Br J Dermatol 2012; 166: 440–2.
- 96 Armstrong AW, Armstrong EJ, Fuller EN et al. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162–8.
- 97 Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586–92.
- 98 Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066–73.
- 99 Alexandroff AB. Tumour immunology up-date: report from the joint annual congress of the British Society for Immunology and the Biochemical Society [Editorial]. Oncol Rep 1997; 4: 661–2.
- 100 Feldman SR. Monitoring psoriasis patients being treated with tumour necrosis factor inhibitors: use your judgment. Br J Dermatol 2011; 165: 229–30.
- 101 Feito-Rodriguez M, de Lucas-Laguna R, Bastian BC et al. Nodular lesions arising in a large congenital melanocytic naevus in a newborn with eruptive disseminated Spitz naevi. Br J Dermatol 2011; 165: 1138–42.
- 102 Aldeen T, Khorshid M. Psoriasis, cardiovascular disease and flow-mediated dilatation. Br J Dermatol 2011; 165: 923–4.
- 103 Ichihara A, Jinnin M, Yamane K et al. microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 2011; 165: 1003–10.
- 104 Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037–43.
- 105 Alexandroff AB, McIntyre CA, Porter JC et al. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer 1998; 77: 1806–11.
- 106 Pouplard C, Gourraud PA, Meyer N et al. Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. Br J Dermatol 2011; 165: 1332–6.
- 107 Spuls PI, Nijsten T. Survival in cancer patients hospitalized for psoriasis: a commentary. Br J Dermatol 2011; 165: 1–2.
- 108 Otuki MF, Reis RC, Cabrini D et al. Patient-reported outcomes in psoriasis research and practice. Br J Dermatol 2011; 165: 1361–2.
- 109 Kinbara M, Nagai Y, Takano-Yamamoto T et al. Cross-reactivity among some metals in a murine metal allergy model. Br J Dermatol 2011; 165: 1022–9.
- 110 Alexandroff AB, Robins RA, Murray A et al. Tumour immunology: false hopes – new horizons? Immunol Today 1998; 19: 247–50.
- 111 Wallingford SC, Alston RD, Birch JM et al. Increases in invasive melanoma in England, 1979–2006, by anatomical site. Br J Dermatol 2011; 165: 859–64.
- 112 Soyland E, Heier I, Rodriguez-Gallego C et al. Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. Br J Dermatol 2011; 164: 344–55.
- 113 Heier I, Soyland E, Krogstad AL et al. Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin. Br J Dermatol 2011; 165: 792–801.
- 114 Alexandroff AB, Jackson AM, Paterson T et al. Role for CD40–CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000; 37: 515–26.
- 115 Kwon HH, Kwon IH, Choi JW et al. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol 2011; 36: 473–8.
- 116 Kwon HH, Kwon IH, Jo SJ et al. Facial psoriasis log-based area and severity index (fPLASI): construct validity of a new facial psoriasis measurement tool. Br J Dermatol 2011; 165: 203–4.
- 117 Shu X, Ji J, Sundquist J et al. Survival in cancer patients hospitalized for psoriasis: a population-based cohort study in Sweden. Br J Dermatol 2011; 165: 129–36.
- 118 Agozzino M, Tosti A, Barbieri L et al. Confocal microscopic features of scarring alopecia: preliminary report. Br J Dermatol 2011; 165: 534–40.
- 119 Alexandroff AB, Gibbs S. Skin deep: report from the annual meeting of the British Society for Investigative Dermatology. Exp Oncol 2007; 29: 162–3.
- 120 Saurat JH, Langley RG, Reich K et al. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 2011; 165: 399–406.
- 121 Inzinger M, Heschl B, Weger W et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011; 165: 640–5.
- 122 Paurobally D, Jason F, Dezfoulian B et al. Melanotan-associated melanoma. Br J Dermatol 2011; 164: 1403–5.
- 123 Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987–1019.
- 124 Burden AD. Health economics and the modern management of psoriasis. Br J Dermatol 2010; 163: 670–1.
- 125 Wylie GR, Burden D. Renbok phenomenon between psoriasis and alopecia areata. Clin Exp Dermatol 2011; 36: 816–17.
- 126 Burden AD. Drug survival rates for tumour necrosis factor-alpha antagonists in psoriasis. Br J Dermatol 2011; 164: 940–1.
